Gyre Therapeutics, Inc. (GYRE) News
Follow Gyre Therapeutics, Inc. (GYRE) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
GYRE - Gyre Therapeutics to Participate in Upcoming September Investor Conferences
GYRE - Gyre Therapeutics to Participate in Upcoming September Investor Conferences
EQUITY | Sep 03, 2026, 11:00 AM UTC
L
Gyre updates presentation on China R&D and F351 progress
Gyre made an updated corporate presentation public, highlighting its China-enabled R&D engine, upcoming IND plans and F351 regulatory progress.
GEOPOLITICS | Sep 01, 2026, 01:04 PM UTC
L
Gyre highlights R&D pipeline progress for degraders and DACs
Gyre says its pipeline of targeted protein degraders and DACs targets unmet needs in oncology, immunology and fibrosis. The company points to China commercial revenues supporting global R&D and cites F351 and ETUARY™ for
GEOPOLITICS | Sep 01, 2026, 12:55 PM UTC
L
Gyre Therapeutics posts updated corporate presentation detailing pipeline progress and China-commercial revenue drivers
Gyre Therapeutics posts updated corporate presentation detailing pipeline progress and China-commercial revenue drivers
GEOPOLITICS | Aug 26, 2026, 01:04 PM UTC
L
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est
Gyre Therapeutics (NASDAQ: GYRE ) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $102.300 million estimate.
EARNINGS | Aug 07, 2026, 12:00 PM UTC